Amazon Go readies for launch as Shanghai’s MobyMart makes the rounds
Trouble sleeping? Vicks reveals why Americans are tossing and turning at night
CINCINNATI – Nearly 9 in 10 Americans (87%) say they have experienced trouble falling asleep, according to a new survey from Vicks ZzzQuil released Monday.
In fact, two-thirds (67%) of Americans state they have trouble falling asleep at least once a month and nearly half (47%) report that they experience this trouble at least once a week. Stress related to family life tops the list of things that keep Americans up at night, with 41% saying family stress prevents them from falling asleep easily, outweighing financial concerns (32%). And almost one-third of Americans (30%) say they have had trouble falling asleep easily because of an experience or interaction with their boss.
“Whether it’s work, family, finances or being connected to devices, we know that sometimes life just keeps you up,” stated Paul Gama, VP North America Personal Health Care, Procter & Gamble. “With nearly one-in-two Americans experiencing trouble falling asleep at least once a week, it is clear that people are not alone in their quest for a good night’s sleep. We want people to know that there is an easy solution, like ZzzQuil, that can help them fall asleep in as little as 20 minutes to get the rest they need.”
Contrary to popular sleep advice, many Americans turn to their devices when they can’t fall asleep. More than a third (36%) report that they log on when they can’t nod off, whether it be surfing the internet (26%), checking or posting on social media (19%) or checking/sending emails (15%).
Additional findings from the survey reveal that of those who tried a sleep-aid, four-in-five (80%) report that a sleeping aid helped them fall asleep more easily and stay asleep all night. On the other hand, less than half of those who tried idealistic approaches had success, with only 46% of those who tried using calming scents in the bedroom and 45% of those who tried drinking hot tea reporting that it helped them fall asleep more easily and stay asleep all night.
ZzzQuil commissioned a survey, conducted online by Harris Poll in December 2016 among more than 2,000 U.S. adults, to better understand how Americans are sleeping and uncover the realistic and idealistic approaches they may take to catch those highly-coveted zzzs.
Clinical trials: Pharma grade chondroitin sulfate effective treatment for osteoarthritis
MADRID — The latest published evidence on osteoarthritis treatment was presented Wednesday at the symposium organized by Bioiberica and IBSA at the Annual European Congress of Rheumatology, here.
A new clinical trial, carried out by IBSA and called CONCEPT (ChONdroitin vs CElecoxib vs Placebo Trial), shows that pharmaceutical grade chondroitin sulfate is as effective as an anti-inflammatory drug (celecoxib) and superior to placebo for pain reduction and improvement of functional disability in patients with knee osteoarthritis.
“A great controversy still exists as to which should be the treatment of choice for osteoarthritis. Analgesics and anti-inflammatory drugs have traditionally been used, but they are increasingly associated to toxicity warnings," stated Tomasz Blicharski, from the Department of Rehabilitation and Traumatology of Lublin University (Poland) and investigator of the study. "This trial has provided statistically significant evidence that treatment with pharmaceutical grade chondroitin sulfate is an effective and safe alternative for long-term treatment of patients with knee osteoarthritis.”
A multicenter, randomized, double blind, controlled and comparative study, conducted by Bioiberica and named MOSAIC (24 MOnth study on Structural changes in knee osteoarthritis Assessed by mrI with Chondroitin sulfate), carried out in five medical centers in Quebec (Canada), shows that chondroitin sulfate delays the disease’s progression and is as effective as celecoxib improving osteoarthritis symptoms.
The study recruited 194 patients suffering from knee osteoarthritis with inflammation and moderate pain, to assess the effects of chondroitin sulfate (1,200 mg/ day) and celecoxib (200 mg/ day) over the loss of cartilage volume in knee osteoarthritis after 24 months. The participants underwent three Quantitative Magnetic Resonance scans and the results revealed that the progression of knee osteoarthritis is slower in patients receiving chondroitin sulfate.
More precisely, this group experienced a statistically significant lower loss of cartilage volume as soon as after the first year of treatment, in comparison with those patients who received the anti inflammatory drug.
The study also evaluated the effects of both products on the disease’s symptoms concluding that both treatments were equally efficient across the entire study, reaching a clinically relevant symptom improvement of around 50%.
“All this latest evidence presented today proves that chondroitin sulfate complies with the requirements that an osteoarthritis treatment must fulfill: it improves pain and functional capacity, and it delays the disease’s progression while having a good safety profile, something essential in a chronic disease such as osteoarthritis,” concluded Jean Pierre Pelletier, main investigator of the MOSAIC study.